COVID-19 and the liver

Liver impairment or abnormal liver function is a common observation among patients with COVID-19. The position statement “Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement” was developed by the Asian-Pacific Working Group for Liver Derangement during COVID-19 pandemic. It provided practice recommendations for specific clinical scenarios such as the use of pharmacological treatment in the case of liver derangement and the management of patients with viral hepatitis and cirrhosis. Moreover, it suggested to include hepatitis serology tests in future patients with COVID-19 since liver dysfunction is commonly discovered in these patients. (Lancet Gastroenterol Hepatol. 2020 Jun 22;S2468-1253(20)30190-4. doi: 10.1016/S2468-1253(20)30190-4. Online ahead of print.)

Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof. Henry CHAN in Department of Medicine & Therapeutics, CUHK. Prof Chan’s research focuses on viral hepatitis, liver fibrosis, liver cancer, anti-viral therapy and fatty liver disease.